
Devendra Hiwase
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Qualifications: MBBS, MD, FRACP, FRCPA, PhD
Practice Responsibilities: Clinical and laboratory haematology
Specialities: Malignant haematology and stem cell transplantation
Site: Royal Adelaide Hospital (RAH), Haematology Department
A/Prof Devendra Hiwase is a Consultant Haematologist at the Royal Adelaide Hospital, Senior Lecturer, University of Adelaide and Senior Research Fellow at South Australia Health Medical Research Institute (SAHMRI). He has a special interest in myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and stem cell transplantation. In 2012, he started the MDS Research Group and South Australian MDS (SA-MDS) registry. Currently, the Group is involved in clinical and translational research projects, including mutational profiling, identifying novel biomarkers, and exploring the impact of nursing case management and comprehensive geriatric assessment on patients with MDS and related disorders.
A/Prof Hiwase’s research focuses on the pathogenesis of myeloid neoplasms and has presented his research findings in multiple international and national meetings and published in peer reviewed journals.
He serves on the editorial board of Leukemia Research and as a reviewer for speciality journals such as Haematologica, Leukemia and Lymphoma, as well as British Journal of Haematology. He is also a subject expert reviewer (external) for NHMRC project grants and has made regular contributions to teaching, provision of specialist medical services, and involvement in local and national committees. Dr Hiwase is a fellow of RACP, RCPA and member of the Australasian Leukaemia and Lymphoma Group (ALLG), Haematology Society of Australasia and New Zealand (HSANZ), American Society of Hematology, and a steering committee member of the national MDS and Aplastic Anaemia registry.
Myeloid neoplasms including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are a group of blood cancers that frequently affect older people. Some patients develop MDS/AML after treatment for their primary cancer (i.e. prostate cancer, breast cancer). This group of patients are known as having therapy-related myeloid neoplasms (T-MN). There are very limited treatment options for T-MN and the survival of these patients is poor. The MDS/AML Research Group focuses on improving the clinical outcome of patients by optimising current therapies and developing new therapies.
Our research group is split into two main arms of MDS/AML research – clinical research and basic science research. The clinical team focuses on patients’ health-related issues including developing global assessment tools to assess patients’ psycho-social needs, quality of life, overall health issues, and treatment-related toxicity. We also aim to improve treatment strategies by studying other factors, such as the management of infections, transfusion support, geriatric support, anticoagulation bleeding support and autoimmune diseases. The basic science team focuses on understanding the molecular pathogenesis of MDS/AML and identify biomarkers (i.e. predisposing mutations, abnormal bone marrow environment caused by long-term chemotherapy and drug resistance proteins) which can potentially change management and developing novel therapeutic approaches.
-
Appointments
Date Position Institution name 2021 - ongoing Clinical Associate Professor The University of Adelaide -
Language Competencies
Language Competency English Can read, write, speak, understand spoken and peer review -
Research Interests
-
Journals
Year Citation 2025 Tefferi, A., Abdelmagid, M., Loscocco, G. G., Fathima, S., Begna, K. H., Al-Kali, A., . . . Guglielmelli, P. (2025). TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. American Journal of Hematology, 100(4), 552-560.
Scopus6 Europe PMC32025 Gharaee, N., Wegrzyn-Woltosz, J., Jiang, J., Akhade, V. S., Bridgers, J., Stubbins, R. J., . . . Karsan, A. (2025). Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm: MECHANISMS OF RESISTANCE. Leukemia, 39(4), 917-928.
2025 Zeidner, J. F., Sallman, D. A., Récher, C., Daver, N. G., Leung, A. Y. H., Hiwase, D. K., . . . Vyas, P. (2025). Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood, blood.2024027408.
Scopus52025 Fathima, S., Abdelmagid, M., Alsugair, A., Begna, K. H., Al-Kali, A., Mangaonkar, A. A., . . . Tefferi, A. (2025). Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. American Journal of Hematology, 100(6), 1010-1018.
Scopus1 Europe PMC12025 Shah, M. V., Arber, D. A., & Hiwase, D. K. (2025). TP53-Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. American Journal of Hematology, 100(S4), 88-115.
Scopus1 Europe PMC12025 Fairbank, J., Kok, C. H., Chhetri, R., Toop, C., Wall, M., Bardy, P., . . . Hiwase, D. (2025). Substantially improved survival for intermediate-risk AML: an Australian statewide network experience spanning 20 years. Blood Global Hematology, 1(1), 100004.
2025 Wiseman, T., Spooner, M., Khanna, S., Hung, K., Toop, C., Kutyna, M. M., . . . Hiwase, D. K. (2025). RBC Transfusion Dependency Refines the Molecular International Prognostic Scoring System for Myelodysplastic Syndrome.. Blood advances, bloodadvances.2025016086.
2025 Shah, M. V., Hung, K., Baranwal, A., Wechalekar, G., Al-Kali, A., Toop, C. R., . . . Hiwase, D. (2025). Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer Journal, 15(1), 11 pages.
2025 Thoms, J. A. I., Yan, F., Hampton, H. R., Davidson, S., Joshi, S., Saw, J., . . . Pimanda, J. E. (2025). Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs. Nature Communications, 16(1), 20 pages.
2025 Shaw, B., Ling, V. Y. M., Hubbard, R. E., Bajel, A., Hiwase, D., Marlton, P., . . . Chua, C. C. (2025). Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statement. Internal Medicine Journal, 55(6), 1013-1018.
2024 Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., . . . Mousa, A. (2024). Response to Letter to the Editor from de Zegher and Ibáñez: 'Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis'.. J Clin Endocrinol Metab, 109(10), e1980-e1981.
2024 Isler, B., Niessen, N., Campbell, D., Toms, A. D., Daneman, N., Manning, L., & Davis, J. S. (2024). Addressing important evidence gaps in the management of prosthetic joint infection: clinician attitudes and equipoise. ANZ Journal of Surgery, 94(7-8), 1211-1213.
2024 Zerella, J. R., Homan, C. C., Arts, P., Lin, X., Spinelli, S. J., Venugopal, P., . . . Hahn, C. N. (2024). Germline ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood, 144(17), 1765-1780.
Scopus6 Europe PMC32024 Wechalekar, M. D., Zhao, L. -P., Kutyna, M. M., Hong, L. E., Li, J., Hung, K., . . . Hiwase, D. K. (2024). Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features. Blood Cancer Journal, 14(1), 116-1-116-5.
Scopus1 Europe PMC12024 Lim, K., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T., . . . Thomas, D. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19(9), e0310641-1-e0310641-19.
2024 Singhal, D., Kutyna, M. M., Hahn, C. N., Shah, M. V., & Hiwase, D. K. (2024). Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment. BLOOD CANCER DISCOVERY, 5(6), 400-416.
Scopus5 Europe PMC42024 Wood, A. J., Boyle, J. A., Barr, E. L. M., Barzi, F., Hare, M. J. L., Titmuss, A., . . . Maple-Brown, L. J. (2024). Corrigendum to “Type 2 diabetes after a pregnancy with gestational diabetes among first nations women in Australia: The PANDORA study” [Diabetes Res. Clin. Pract. 181 (2021) 109092] (Diabetes Research and Clinical Practice (2021) 181, (S0168822721004514), (10.1016/j.diabres.2021.109092)). Diabetes Research and Clinical Practice, 213, 2 pages.
2024 Hong, L. E., Wechalekar, M. D., Kutyna, M. M., Small, A., Lim, K., Thompson-Peach, C. A., . . . Hiwase, D. K. (2024). IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation. Blood, 143(18), 1873-1877.
Scopus5 Europe PMC22024 Venugopal, P., Arts, P., Fox, L. C., Simons, A., Hiwase, D. K., Bardy, P. G., . . . Scott, H. S. (2024). Unravelling Facets of MECOM-Associated Syndrome: Somatic Genetic Rescue, Clonal Hematopoiesis and Phenotype Expansion. Blood Advances, 8(13), 3437-3443.
Scopus1 Europe PMC12024 Tate, K., Penconek, T., Booth, A., Harvey, G., Flynn, R., Lalleman, P., . . . Jones, K. (2024). Contextually appropriate nurse staffing models: A realist review protocol. BMJ Open, 14(5), 9 pages.
Scopus12024 Miwa, A., Wakamori, M., Ariyoshi, T., Okada, Y., Shirouzu, M., Umehara, T., & Kamiya, K. (2024). Efficiency of transcription and translation of cell-free protein synthesis systems in cell-sized lipid vesicles with changing lipid composition determined by fluorescence measurements. Scientific Reports, 14(1), 10 pages.
Scopus5 Europe PMC22024 Walker, H. N., Caly, L., Savic, I., Aziz, A., Tran, T., Whitley, M., . . . Lim, C. K. (2024). Recovery of yellow fever virus whole genome from an individual with severe vaccine-associated viscerotropic disease. Lancet Microbe, 5(5), e414.
Scopus12024 Gaborit, L., Kalyanasundaram, K., Vu, J., Basam, A., Elhadi, M., Wright, D., . . . Larkin, M. (2024). Patterns of opioid use after surgical discharge: a multicentre, prospective cohort study in 25 countries. Anaesthesia, 79(9), 924-936.
Scopus5 Europe PMC52024 Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., . . . Badar, T. (2024). What have we learned about TP53-mutated acute myeloid leukemia?. Blood Cancer Journal, 14(1), 9 pages.
Scopus10 Europe PMC92024 Tefferi, A., Fleti, F., Chan, O., Al Ali, N. H., Al-Kali, A., Begna, K. H., . . . Komrokji, R. (2024). TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). British Journal of Haematology, 204(4), 1243-1248.
Scopus5 Europe PMC42024 McQuilten, Z., Heritier, S., Fox, L., Fox, V., Young, L., Blombery, P., . . . Wood, E. (2024). Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open, 14(1), e076246-1-e076246-11.
Scopus3 Europe PMC52024 Kok, C. H., Yeung, D. T., & Hiwase, D. K. (2024). Special Issue “Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms”. International Journal of Molecular Sciences, 25(4), 5 pages.
Scopus12024 Tiong, I. S., Hiwase, D. K., Abro, E., Bajel, A., Palfreyman, E., Beligaswatte, A., . . . Wei, A. H. (2024). Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology, 42(18), 2161-2173.
Scopus15 Europe PMC142023 Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., . . . Majeti, R. (2023). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery, 13(2), 496-515.
Scopus36 WoS7 Europe PMC292023 Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091.
Scopus21 WoS7 Europe PMC192023 Fleti, F., Chan, O., Singh, A., Abdelmagid, M. G., Al-Kali, A., Elliott, M. A., . . . Tefferi, A. (2023). TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. American Journal of Hematology, 98(4), E76-E79.
Scopus6 WoS1 Europe PMC52023 de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., . . . Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117-3127.
Scopus77 WoS11 Europe PMC552023 Kutyna, M. M., Loone, S., Saunders, V. A., White, D. L., Kok, C. H., & Hiwase, D. K. (2023). Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences, 24(4), 3553-1-3553-14.
Scopus32023 Montarello, N., Leslie, A., Chhetri, R., Friel, O., Singhal, D., Ross, D. M., . . . Hiwase, D. K. (2023). Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes.. Blood Advances, 7(13), 3032-3035.
Scopus1 Europe PMC12023 Baranwal, A., Chhetri, R., Yeung, D., Clark, M., Shah, S., Litzow, M. R., . . . Shah, M. V. (2023). Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.. Bone Marrow Transplant, 58(7), 769-776.
Scopus11 WoS1 Europe PMC112023 Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., . . . Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51-1-51-9.
Scopus22 WoS2 Europe PMC202023 Homan, C. C., Drazer, M. W., Yu, K., Lawrence, D. M., Feng, J., Arriola-Martinez, L. A., . . . Brown, A. L. (2023). Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Advances, 7(20), 6092-6107.
Scopus22 Europe PMC152023 Eadie, L. N., Rehn, J. A., Schutz, C. E., Heatley, S. L., Kutyna, M. M., Hiwase, D. K., . . . Yeung, D. T. (2023). Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling. British Journal of Haematology, 203(2), 282-287.
Europe PMC12023 Sharplin, K., Proudman, W., Chhetri, R., Tran, E. N. H., Choong, J., Kutyna, M., . . . Hiwase, D. (2023). A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data. Cancers, 15(16), 1-14.
Scopus3 Europe PMC22023 Loo, S., Roberts, A. W., Anstee, N. S., Kennedy, G. A., He, S., Schwarer, A. P., . . . Wei, A. H. (2023). Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood, 142(23), 1960-1971.
Scopus15 WoS1 Europe PMC62023 Fox, L. C., McQuilten, Z. K., Firkin, F., Fox, V., Badoux, X., Bajel, A., . . . Wood, E. M. (2023). The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry. Best Practice and Research: Clinical Haematology, 36(4), 101516-1-101516-10.
Scopus2 Europe PMC12023 Saygin, C., Roloff, G. W., Hahn, C. N., Chhetri, R., Gill, S. I., Elmariah, H., . . . Godley, L. A. (2023). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances, 7(4), 549-554.
Scopus34 WoS10 Europe PMC252023 Luo, S., Png, G. K., Ostle, N. J., Zhou, H., Hou, X., Luo, C., . . . Bardgett, R. D. (2023). Grassland degradation-induced declines in soil fungal complexity reduce fungal community stability and ecosystem multifunctionality. SOIL BIOLOGY & BIOCHEMISTRY, 176, 12 pages.
2023 Bakhai, M. P., & Rifat, A. H. (2023). Design and Analysis of Generic UAV Composite Winglet Structures. Journal of the Institution of Engineers India Series C, 104(5), 967-977.
Scopus22022 Selby, P. R., Warner, M. S., Peake, S. L., Bardy, P., Hiwase, D., Singhal, D., . . . Shakib, S. (2022). Optimising antifungal prophylaxis in allogeneic stem cell transplantation - a cohort study of two different approaches. Transplant Infectious Disease, 24(6), 1-11.
Scopus2 Europe PMC22022 Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689.
Scopus15 WoS4 Europe PMC132022 Beckmann, K., Kearney, B. J., Yeung, D., Hiwase, D., Li, M., & Roder, D. M. (2022). Changes in five-year survival for people with acute leukaemia in South Australia, 1980-2016. Medical Journal of Australia, 216(6), 296-302.
Scopus8 WoS5 Europe PMC82022 Shah, M. V., Chhetri, R., Dholakia, R., Kok, C. H., Gangat, N., Alkhateeb, H. B., . . . Hiwase, D. (2022). Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. American Journal of Hematology, 97(8), 1013-1022.
Scopus10 WoS5 Europe PMC92022 Baranwal, A., Hahn, C. N., Shah, M. V., & Hiwase, D. K. (2022). Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms. Current Hematologic Malignancy Reports, 17(6), 254-265.
Scopus12 WoS3 Europe PMC122021 Ravandi, F., Roboz, G. J., Wei, A. H., Döhner, H., Pocock, C., Selleslag, D., . . . Dombret, H. (2021). Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Journal of Hematology and Oncology, 14(1), 14 pages.
Scopus16 WoS8 Europe PMC102021 Samaraweera, S. E., Wang, P. P. S., Li, K. L., Casolari, D. A., Feng, J., Pinese, M., . . . D'Andrea, R. J. (2021). Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood, 138(22), 2293-2298.
Scopus9 WoS5 Europe PMC82021 Tiong, I. S., Dillon, R., Ivey, A., Kuzich, J. A., Thiagarajah, N., Sharplin, K. M., . . . Wei, A. H. (2021). Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 5(23), 5107-5111.
Scopus31 WoS15 Europe PMC282021 Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256.
Scopus45 WoS26 Europe PMC372021 Sharplin, K., Wee, L. Y. A., Singhal, D., Edwards, S., Danner, S., Lewis, I., . . . Hiwase, D. K. (2021). Outcomes and health care utilization of older patients with acute myeloid leukemia.. Journal of geriatric oncology, 12(2), 243-249.
Scopus5 WoS4 Europe PMC82021 Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207.
Scopus59 WoS40 Europe PMC372021 Weigelt, A., Mommer, L., Andraczek, K., Iversen, C. M., Bergmann, J., Bruelheide, H., . . . McCormack, M. L. (2021). An integrated framework of plant form and function: the belowground perspective. NEW PHYTOLOGIST, 232(1), 42-59.
Europe PMC1082020 Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Friel, O., Pham, A., Salvi, A., . . . Hiwase, D. K. (2020). The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. Transfusion, 60(10), 2192-2198.
Scopus12 WoS8 Europe PMC62020 Brown, A. L., & Hiwase, D. K. (2020). What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening. Leukemia Research, 96, 3 pages.
Scopus4 WoS3 Europe PMC22020 Marinelli, T., Wee, L. Y. A., Rowe, E., Chhetri, R., Friel, O., Higgins, G., . . . Hiwase, D. K. (2020). Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 26(4), 782-788.
Scopus20 WoS10 Europe PMC122020 Kuzmanovic, T., Patel, B. J., Sanikommu, S. R., Nagata, Y., Awada, H., Kerr, C. M., . . . Radivoyevitch, T. (2020). Genomics of therapy-related myeloid neoplasms. Haematologica, 105(3), E98-E101.
Scopus33 WoS19 Europe PMC262020 Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C. -E., . . . Scott, H. S. (2020). RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 4(6), 1131-1144.
Scopus112 WoS65 Europe PMC852020 Molga, A., Wall, M., Chhetri, R., Wee, L. Y., Singhal, D., Edwards, S., . . . Hiwase, D. (2020). Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. Journal of Geriatric Oncology, 11(1), 114-120.
Scopus38 WoS25 Europe PMC252020 Molga, A., Wall, M., Wee, L. Y. A., Chhetri, R., Singhal, D., Singhal, N., . . . Hiwase, D. (2020). Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes.. Journal of geriatric oncology, 11(1), 128-130.
Scopus5 WoS4 Europe PMC52020 Roberts, M. B., Bak, N., Wee, L. Y. A., Chhetri, R., Yeung, D. T., Lewis, I., & Hiwase, D. K. (2020). Clinical Effectiveness of Conjugate Pneumococcal Vaccination In Hematopoietic Stem Cell Transplant Recipients.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(2), 421-427.
Scopus14 WoS10 Europe PMC72020 Brown, A. L., Hahn, C., Hiwase, D., Godley, L. A., & Scott, H. S. (2020). Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. LEUKEMIA & LYMPHOMA, 61(1), 2 pages.
Scopus2 WoS2 Europe PMC12019 Ho, P. J., Hiwase, D., Ramakrishna, R., Viiala, N., Solterbeck, A., Traficante, R., . . . Bowden, D. K. (2019). Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: The TIMES study. HemaSphere, 3(3), 11 pages.
Scopus8 WoS8 Europe PMC52019 Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., . . . Hiwase, D. K. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 33(12), 2842-2853.
Scopus48 WoS38 Europe PMC352019 Shanmuganathan, N., Braley, J. A., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., . . . Branford, S. (2019). Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood, 134(1), 85-89.
Scopus25 WoS19 Europe PMC152019 Germing, U., Oliva, E. N., Hiwase, D., & Almeida, A. (2019). Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. Hemasphere, 3(6), 9 pages.
Scopus34 WoS17 Europe PMC152019 Kenealy, M., Hertzberg, M., Benson, W., Taylor, K., Cunningham, I., Stevenson, W., . . . Seymour, J. F. (2019). Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. HAEMATOLOGICA, 104(4), 700-709.
Scopus15 WoS12 Europe PMC102019 Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances, 3(3), 370-374.
Scopus7 WoS4 Europe PMC32019 Clucas, D. B., Fox, L. C., Wood, E. M., Hong, F. S., Gibson, J., Bajel, A., . . . Wood, E. (2019). Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. INTERNAL MEDICINE JOURNAL, 49(2), 152-159.
Scopus13 WoS8 Europe PMC102019 Chhetri, R., Wee, L. Y. A., Sinha, R., Kutyna, M. M., Pham, A., Stathopoulos, H., . . . Hiwase, D. K. (2019). Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: Prevalence, characteristic and significance. Haematologica, 104(10), E451-E454.
Scopus18 WoS12 Europe PMC62018 New-Tolley, J., Smith, C., Koszyca, B., Otto, S., Maundrell, A., Bardy, P., . . . Limaye, V. (2018). Inflammatory myopathies after allogeneic stem cell transplantation. Muscle and Nerve, 58(6), 790-795.
Scopus18 WoS15 Europe PMC72018 Hiwase, D., & Ross, D. (2018). Success is built on failures: tackling the challenge of ponatinib failure. Leukemia and Lymphoma, 59(6), 1279-1281.
Scopus1 WoS1 Europe PMC12018 Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . . Hughes, T. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leukemia Research, 67, 109-115.
Scopus14 WoS9 Europe PMC72018 Schwarer, A. P., Butler, J., Jackson, K., Beligaswatte, A., Martin, L., Kennedy, G., . . . Marlton, P. (2018). A Comparison of High-Dose Cytarabine during Induction Versus Consolidation Therapy in Newly Diagnosed AML. Hemasphere, 2(6), 8 pages.
Scopus2 WoS2 Europe PMC22017 Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 102(12), 2021-2029.
Scopus48 WoS31 Europe PMC282017 Hiwase, D., Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., . . . Germing, U. (2017). Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. American Journal of Hematology, 92(6), 508-514.
Scopus34 WoS24 Europe PMC172017 Hiwase, D. (2017). The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. Leukemia Research, 57, 102-103.
2017 Shanmuganathan, N., Hiwase, D., & Ross, D. (2017). Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leukemia and Lymphoma, 58(12), 2799-2810.
Scopus19 WoS17 Europe PMC122017 Cheah, J., Hahn, C., Hiwase, D., Scott, H., & Brown, A. (2017). Myeloid neoplasms with germline DDX41 mutation. International Journal of Hematology, 106(2), 163-174.
Scopus78 WoS59 Europe PMC642016 Dawar, S., Shahrin, N., Sladojevic, N., D'Andrea, R., Dorstyn, L., Hiwase, D., & Kumar, S. (2016). Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice. Cell Death and Disease, 7(12), e2509-1-e2509-9.
Scopus25 WoS21 Europe PMC252016 Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . . . White, D. (2016). TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 30(6), 1263-1272.
Scopus44 WoS32 Europe PMC262015 Hahn, C., Ross, D., Feng, J., Beligaswatte, A., Hiwase, D., Parker, W., . . . Scott, H. (2015). A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia, 29(10), 2101-2104.
Scopus29 WoS23 Europe PMC282015 Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923.
Scopus87 WoS67 Europe PMC532015 Hahn, C., Venugopal, P., Scott, H., & Hiwase, D. (2015). Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunological Reviews, 263(1), 257-278.
Scopus42 WoS33 Europe PMC382015 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85.
Scopus30 WoS27 Europe PMC242014 Nievergall, E., Ramshaw, H., Yong, A., Biondo, M., Busfield, S., Vairo, G., . . . Hiwase, D. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123(8), 1218-1228.
Scopus89 WoS77 Europe PMC682014 Hiwase, D. K., Hahn, C. N., Babic, M., Moore, S., Butcher, C. M., Kutyna, M. M., . . . Scott, H. S. (2014). Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes. BLOOD, 124(21), 3 pages. 2013 Puccini, J., Shalini, S., Voss, A., Gatei, M., Wilson, C., Hiwase, D., . . . Kumar, S. (2013). Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 110(49), 19920-19925.
Scopus62 WoS53 Europe PMC522013 Hiwase, D., Saunders, V., Nievergall, E., Ross, D., White, D., & Hughes, T. (2013). Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Haematologica, 98(6), 896-900.
Scopus8 WoS9 Europe PMC72013 White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204.
Scopus8 WoS7 Europe PMC62013 Chow, A., Lee, C., Hiwase, D., To, L., & Horvath, N. (2013). Relapsed multiple myeloma: who benefits from salvage autografts?. Internal Medicine Journal, 43(2), 156-161.
Scopus15 WoS12 Europe PMC102013 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705.
WoS12012 Hiwase, D. K., & Hughes, T. P. (2012). Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 53(7), 1251-1252.
Scopus3 WoS1 Europe PMC12011 To, L., Levesque, J., Herbert, K., Winkler, I., Bendall, L., Hiwase, D., . . . Lewis, I. (2011). Mobilisation strategies for normal and malignant cells. Pathology, 43(6), 547-565.
Scopus10 WoS7 Europe PMC72011 Hiwase, D., Yeung, D., & White, D. (2011). Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Review of Hematology, 4(3), 285-299.
Scopus6 WoS6 Europe PMC52011 Foot, N., Leong, Y., Dorstyn, L., Dalton, H., Ho, K., Zhao, L., . . . Kumar, S. (2011). Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis. Blood, 117(2), 638-646.
Scopus41 WoS33 Europe PMC372010 Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778.
Scopus48 WoS42 Europe PMC372010 Hiwase, D., White, D., Zrim, S., Saunders, V., Vaz de Melo, J., & Hughes, T. (2010). Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 24(3), 658-660.
Scopus27 WoS25 Europe PMC242009 Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL<sup>+</sup> cells. Leukemia, 23(6), 1205-1206.
Scopus17 WoS15 Europe PMC122008 Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888.
Scopus168 WoS145 Europe PMC1342008 Hiwase, D., Hiwase, S., Bailey, M., Bollard, G., & Schwarer, A. (2008). The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy, 10(5), 507-517.
Scopus20 WoS16 Europe PMC162008 Hiwase, D., Hiwase, S., Bailey, M., Bollard, G., & Schwarer, A. (2008). Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 14(1), 116-124.
Scopus78 WoS67 Europe PMC612007 Hiwase, D. K., Bollard, G., Hiwase, S., Bailey, M., Muirhead, J., & Schwarer, A. P. (2007). Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy, 9(6), 539-547.
Scopus47 WoS45 Europe PMC372002 Mohite, U., Pathare, A., Al Kindi, S., Hiwase, D., Vadakkepat, N., & Knox-Macaulay, H. (2002). Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia. Haematologia, 32(4), 495-499. 2002 Knox-Macaulay, H. H. M., Hiwase, D., Nusrat, N., & Ganesh, A. (2002). Pseudotumour cerebri occurring before treatment of acute promyelocytic leukaemia with all-trans-retinoic acid (ATRA). Haematologia, 32(1), 81-85.
Scopus3 Europe PMC22000 Ghosh, K., Mitra, S., & Hiwase, D. (2000). Choroidal infiltrates simulating fundal changes of acute leukemia during hematological recovery following high-dose chemotherapy in acute myelomonocytic leukemia in remission. American Journal of Hematology, 63(1), 42-45.
Scopus3 Europe PMC42000 Ghosh, K., Daar, S., Hiwase, D., & Nusrat, N. (2000). Primary Pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient. Haematologia, 30(1), 69-72.
Scopus12 Europe PMC52000 Ghosh, K., Hiwase, D., & Muirhead, D. (2000). Intense eosinophilia with abnormal ultrastructure as presenting manifestation of acute lymphoblastic leukemia. Haematologia, 30(2), 137-141.
2000 Ghosh, K., Khanduri, U., Hiwase, D., Venugopal, S., & Muirhead, D. (2000). Acute Myelomonocytic Leukaemia with Pseudo-Chediak-Higashi inclusions in leukaemic blasts report of an unusual case. Haematologia, 30(3), 229-234.
Scopus12000 Kulkarni, K., Parikh, P. M., Hiwase, D. K., Pai, V. R., Gopal, R., Saikia, T. K., & Advani, S. H. (2000). Letter to editor (multiple letters). Indian Journal of Hematology and Blood Transfusion, 18(1), 22-23. 1999 Ghosh, K., Muirhead, D., Christie, B., & Hiwase, D. (1999). Ultrastructural changes in peripheral blood neutrophils in a patient receiving ganciclovir for CMV pneumonitis following allogenic bone marrow transplantation. Bone Marrow Transplantation, 24(4), 429-431.
Scopus2 Europe PMC21987 Fabry, M. E., Kaul, D. K., Davis, L., Gore, J. C., Brown, M., & Nagel, R. L. (1987). An animal model for sickle cell vaso-occlusion: a study using NMR and technetium imaging.. Progress in Clinical and Biological Research, 240, 297-304.
Scopus8 Europe PMC51985 Desai, M. H., Brown, M., & Mlcak, R. (1985). Reduction of smoke-induced lung injury with dimethylsulfoxide and heparin treatment. Surgical Forum, VOL. 36, 103-104.
Scopus12 -
Book Chapters
Year Citation 2024 Anikeeva, O., & Bi, P. (2024). Population health perspective on extreme weather events and emergency medical services. In J. Braithwaite, Y. Zurynski, & C. Smith (Eds.), Routledge Handbook of Climate Change and Health System Sustainability (pp. 133-140). Routledge.
DOI2011 Hiwase, D. K., & Hughes, T. P. (2011). Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. In Leukemias Principles and Practice of Therapy (pp. 281-295). Wiley.
DOI2008 Hiwase, D. K., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117). -
Conference Papers
Year Citation 2024 Pratiwi, G. R., Gunawan, I., Agustiani, N., Margaret, S., & Widowati, L. R. (2024). Upland Rice Productivity Affected by Some Ameliorants in Two Different Soil Types with Al Problem. In Aip Conference Proceedings Vol. 2957 (pp. 100013). AIP Publishing.
DOI2024 Prawestri, A. D., Handayani, T., Leksonowati, A., Riastiwi, I., Gunawan, I., & Ridwan. (2024). Agronomic Traits and Leaves Nutritional Content Variation of Indonesian Moringa (Moringa oleifera Lam.). In Aip Conference Proceedings Vol. 2957 (pp. 040028). AIP Publishing.
DOI2023 Susanto, U., Lestari, P., Rohaeni, W. R., & Gunawan, I. (2023). Thermogradient-Base Screening Technique for Evaluating High-Temperature Tolerance in Rice Genotypes during the Early Growth Stage. In Aip Conference Proceedings Vol. 2972 (pp. 060010). AIP Publishing.
DOI2023 Gunawan, I., & Muhroji. (2023). Analysis of the HOTS mathematics learning evaluation questions for elementary schools. In Aip Conference Proceedings Vol. 2727 (pp. 020068). AIP Publishing.
DOI2021 Hainsworth, J., Friedman, C. F., Kurzrock, R., Spigel, D. R., Burris, H., Sweeney, C. J., . . . Swanton, C. (2021). Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort.. In CANCER RESEARCH Vol. 81 (pp. 2 pages). PA, Philadelphia: AMER ASSOC CANCER RESEARCH. 2020 Geng, J. -H., Pomerantz, M., Penney, K., Nabi, J., Sweeney, C., Mucci, L., & Kibel, A. (2020). IMPACT OF METABOLIC DISEASES AND DRUGS ON PROSTATE CANCER PATIENTS RECEIVING ANDROGEN DEPRIVATION THERAPY. In JOURNAL OF UROLOGY Vol. 203 (pp. E1222-E1223). DC, Washington: LIPPINCOTT WILLIAMS & WILKINS. 2020 Ravandi, F., Pocock, C., Selleslag, D., Montesinos, P., Sayar, H., Musso, M., . . . Dombret, H. (2020). Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S187-S188). CIG MEDIA GROUP, LP.
WoS12019 Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Salvi, A., Mcrae, S., Roxby, D. J., . . . Hiwase, D. K. (2019). The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Sharplin, K., Wee, L. Y. A., Edwards, S., Danner, S., Yong, A. S., Singhal, D., & Hiwase, D. (2019). Outcomes and Healthcare Utilization in Older Patients with Acute Myeloid Leukemia (AML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S224). CIG MEDIA GROUP, LP.
DOI2019 Singhal, D., Hahn, C. N., Moma, L. D., Wee, L. Y. A., Chhetri, R., Babic, M., . . . Hiwase, D. K. (2019). Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12019 Brown, A. L., Babic, M., Schreiber, A., Feng, J., Dobbins, J., Arts, P., . . . Scott, H. S. (2019). Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12019 Hahn, C. N., Babic, M., Brautigan, P. J., Venugopal, P., Phillips, K., Dobbins, J., . . . Scott, H. S. (2019). Australian Familial Haematological Cancer Study - Findings from 15 Years of Aggregated Clinical, Genomic and Transcriptomic Data. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22019 Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Giri, P., . . . Hiwase, D. K. (2019). An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Unnikrishnan, A., Lim, X. Y., Joshi, S., Nunez, A. C., Vaughan, L., Pickford, R., . . . Pimanda, J. (2019). <i>In Vivo</i> Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Kutyna, M., Paton, S., Gronthos, S., & Hiwase, D. (2019). ABERRANT BONE MARROW MICROENVIRONMENT IN THERAPY RELATED MYELOID NEOPLASM. In EXPERIMENTAL HEMATOLOGY Vol. 76 (pp. E3-E4). ELSEVIER SCIENCE INC. 2018 Bryce, A. H., Chen, Y. -H., Liu, G., Carducci, M. A., Jarrard, D. F., Garcia, J. A., . . . Sweeney, C. (2018). Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
DOI2018 Komura, K., Sweeney, C., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. (2018). DNA REPLICATION STRESS BY THE LOSS OF MALE SPECIFIC HISTONE DEMETHYLASE 'KDM5D' IN AGGRESSIVE PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 199 (pp. E365). CA, San Francisco: ELSEVIER SCIENCE INC. 2018 Allott, E., Noonan, E., Gonzalez-Feliciano, A., Markt, S., Wilson, K., Ahearn, T., . . . Mucci, L. (2018). MOLECULAR TUMOR PROFILING TO IDENTIFY MECHANISMS LINKING STATINS WITH LOWER RISK OF LETHAL PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 199 (pp. E261-E262). CA, San Francisco: ELSEVIER SCIENCE INC. 2018 Oguntola, I., Olubeko, S., & Sweeney, C. (2018). SlimNets: An Exploration of Deep Model Compression and Acceleration. In 2018 IEEE HIGH PERFORMANCE EXTREME COMPUTING CONFERENCE (HPEC) (pp. 6 pages). MA, Waltham: IEEE. 2018 Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP.
DOI2017 Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Singhal, D., Kutyna, M. M., Chhetri, R., Wee, A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS). In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Al-Kali, A., Hiwase, D., Baer, M. R., Greenberg, P., Shortt, J., Collins, R., . . . Silverman, L. R. (2017). Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA). In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12017 Singhal, D., Wee, A., Parker, W., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2017). Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to <i>TP53</i> Mutations in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS22017 Hahn, C. N., Wee, A., Babic, M., Feng, J., Wang, P., Kutyna, M. M., . . . Scott, H. S. (2017). Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS22016 Schwarer, A. P., Wight, J., Jackson, K., Beligaswatte, A. M., Butler, J. P., Kennedy, G., . . . Marlton, P. (2016). High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?. In BLOOD Vol. 128 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS232016 Brown, A. L., Hahn, C. N., Carmichael, C., Wilkins, E., Babic, M., Chong, C. -E., . . . Scott, H. S. (2016). Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline <i>RUNX1</i> Mutations. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Garcia-Manero, G., Fenaux, P., Al-Kali, A., Navada, S. C., Baer, M. R., Raza, A., . . . Silverman, L. R. (2016). Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS92016 Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., Nath, S., . . . Germing, U. (2016). RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients: analysis of South Australian and Dusseldorf MDS registries. In Proceedings of the 58th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood Vol. 128 (pp. 1998). San Diego, CA: American Society of Hematology. 2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Nath, S. V., . . . Germing, U. (2016). RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. 2016 Singhal, D., Wee, L. A., Parker, W. T., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2016). The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2015 Singhal, D., Hague, S., Roxby, D., Wee, L. A., Lee, O. -L., Sinha, R., . . . Hiwase, D. K. (2015). RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hahn, C. N., Babic, M., Schreiber, A. W., Kutyna, M. M., Wee, L. A., Brown, A. L., . . . Hiwase, D. (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS32015 Hoi, P. J., Hiwase, D., Ramakrishna, A., Viiala, N., Ross, D. M., Zor, E., & Gervasio, O. L. (2015). Prevalence of Cardiac and H sis in Australian Patients with Transfusion-Dependent Anemias or No -Dependent Thalassemia, As Assessed By MRI (the TIMES study). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hiwase, D., Hahn, C., Babic, M., Moore, S., Singhal, D., Kutyna, M., . . . Scott, H. (2015). MULTIPLE MUTATIONS IN THE SAME GENE SUGGEST CLONAL DIVERSITY AND IS ASSOCIATED WITH POOR PROGNOSIS IN MDS. In LEUKEMIA RESEARCH Vol. 39 (pp. S77-S78). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2015 Hiwase, D., Moore, S., Kutyna, M., Fraser, R., Singhal, D., Chhetri, R., . . . Scott, H. (2015). SNP-MICROARRAY OF PERIPHERAL BLOOD-GRANULOCYTES DNA CAN DETECT CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS). In LEUKEMIA RESEARCH Vol. 39 (pp. S79-S80). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2015 Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2015). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. In LEUKEMIA RESEARCH Vol. 39 (pp. S5). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS32015 Hiwase, D., Moore, S., Hahn, C., Kutyna, M., Van der Hoek, M., Fraser, R., . . . Scott, H. (2015). TARGETED MUTATION SEQUENCING AND SNP-MICRORRAY CAN IDENTIFY POOR PROGNOSTIC GROUP IN IPSS-LOWER RISK GROUP. In LEUKEMIA RESEARCH Vol. 39 (pp. S78-S79). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2013 Hiwase, D. K., Kutyna, M. M., Chhetri, R., Howell, S., Harrison, P. B., Nath, S. V., . . . To, L. B. (2013). Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS42011 Chow, A. W. S., Lee, C. H. S., Hiwase, D. K., To, L. B., & Horvath, N. (2011). Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?. In BLOOD Vol. 118 (pp. 1319). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS12010 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS102010 Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. 2010 Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology.
DOI2009 Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY. 2008 Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY. 2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS72007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology.
DOI -
Conference Items
Year Citation 2019 Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Kutyna, M., Wechalekar, M., . . . Proudman, S. (2019). MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATOLOGICAL DISORDERS. Poster session presented at the meeting of ANNALS OF THE RHEUMATIC DISEASES. Madrid, SPAIN: BMJ PUBLISHING GROUP.
DOI2019 Kutyna, M. M., Wee, A., Paton, S., Cakouros, D., Arthur, A., Chhetri, R., . . . Hiwase, D. K. (2019). Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN). Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22018 Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS52018 Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Singhal, N., . . . Hiwase, D. K. (2018). Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS22018 Singhal, D., Wee, A., Kutyna, M. M., Babic, M., Chhetri, R., Parker, W., . . . Hiwase, D. K. (2018). Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI2018 Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Wechalekar, M. D., Proudman, S., & Hiwase, D. K. (2018). The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI2018 Pradhan, A., Chhetri, R., Wee, A., Malhotra, R., Singhal, D., Nelson, R., . . . Hiwase, D. K. (2018). Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI2018 Chhetri, R., Wee, A., Sinha, R., Kutyna, M. M., Gupta, S., Nath, L., . . . Hiwase, D. K. (2018). Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS12017 Singhal, D., Wee, L. A., Babic, M., Parker, W., Moore, S., Feng, J., . . . Hiwase, D. (2017). THERAPY RELATED MYELOID NEOPLASMS (T-MN) SHOW HIGH MUTATION FREQUENCY AND A SPECTRUM DIFFERENT FROM PRIMARY MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2017 Singhal, D., Chhetri, R., Wee, L. A., Kutyna, M., Nath, S., & Hiwase, D. (2017). IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED SURVIVAL IN LOWER RISK MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2016 Singhal, D., Moore, S., Kutyna, M., Chhetri, R., Wee, L. A., Gray, J., . . . Hiwase, D. (2016). THERAPY RELATED MYELOID NEOPLASM FOLLOWING RADIOTHERAPY HAS HIGHER INCIDENCE OF POOR RISK CYTOGENETICS AND ARE ASSOCIATED WITH POOR SURVIVAL COMPARED TO DE NOVO MDS CASES. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Ho, P. J., Hiwase, D., Ramakrishna, R., Viiala, N., Ross, D., Zor, E., . . . Bowden, D. K. (2016). THE IMPACT OF CARDIAC AND HEPATIC MRI ASSESSMENT ON THE CLINICAL MANAGEMENT OF AUSTRALIAN PATIENTS WITH TRANSFUSION DEPENDENT ANEMIAS OR NON-TRANSFUSION-DEPENDENT THALASSEMIA IN THE TIMES STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2014 Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2014). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE IN HIGHER RISK MDS IS DELIVERABLE WITH HIGHER RESPONSE RATES; FIRST ANALYSIS OF THE ALLG MDS4 RANDOMISED PHASE II STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
DOI WoS12014 Hiwase, D. K., Singhal, D., Chhetri, R., Kutyna, M. M., Harrison, P. B., Nath, S. V., . . . To, L. B. (2014). Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. 2013 Hiwase, D., Kutyna, M., Carr, T., Harrison, P., Melo, J. V., Bardy, P., & To, L. B. (2013). Transfusion dependency is associated with inferior outcome in very low- and low-risk IPSS-R patients. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
DOI2013 Kenealy, M., Seymour, J. F., Benson, W., Stevenson, W., Eek, R., Zantomio, D., . . . Zannino, D. (2013). The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS12013 Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS82013 White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. 2012 Amin, T., Elias, T., Hiwase, D., & Otto, S. (2012). SYSTEMIC MASTOCYTOSIS IS ASSOCIATED WITH MINIMAL CHANGE DISEASE. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL. 2012 Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI2012 Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS32012 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS8 -
Preprint
Year Citation 2024 Munn, Z., & Moore, L. (2024). Views and opinions regarding e-cigarettes and vaping: a focus group study in South Australia.
DOI
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS and therapy-related myeloid neoplasms. Miller Bequest HSCGB (2020). $30,800. Devendra Hiwase.
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS and therapy-related myeloid neoplasms. Sail for Cancer HSCGB (2020). $30,000. Devendra Hiwase.
- Precision Medicine for Chronic Myelomonocytic Leukaemia: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort. MRFF Rare Cancers, Rare Diseases and Unmet Need APP1201012 (2019). $1,619,122. Timothy Hughes, Devendra Hiwase, David Ross, Daniel Thomas, David Yeung, Steven Lane, Agnes Yong, Angel Lopez, Timothy Hercus, John Reynolds.
- Understanding molecular pathogenesis of therapy related myeloid neoplasm. MRFF Investigator Grants MRF1195517 (2019). $560,105. Devendra Hiwase
- South Australian MDS-Database. Grant Funding, Novartis Pharmaceuticals Australia Pty Limited (2018). $60,000. Devendra Hiwase
- To evaluate the frequency of clonal haematopoiesis and risk of therapy-related myeloid neoplasm in primary cancer patients treated with chemo/radiotherapy. RAH Research Committee Clinical Project Grant (2018). $50,000. Nimit Singhal, Deepak Singhal, Devendra Hiwase, Chris Hahn, Hamish Scott
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS. Miller Bequest HSCGB (2018). $75,886.50. Devendra Hiwase.
- Determine the clinical impact of mutation profile in ICUS, MDS and t-MN. Sail for Cancer HSCGB (2018). $38,220.67. Devendra Hiwase.
- Molecular profiling to improve diagnosis and develop therapeutic strategy for MDS/MPN overlap syndrome. Miller Bequest HSCGB (2017). $73,718. Ian Lewis, Devendra Hiwase, Amilia Wee
- Molecular Profiling of Idiopathic Cytopenia Undetermined Significance to Improve Diagnosis and Develop Prognostic Model. Sail for Cancer HSCGB (2017). $54,345. Ian Lewis, Devendra Hiwase, Amilia Wee
I lead the MDS/AML research group in the South Australian Health and Medical Institute (SAHMRI) and supervise a research assistant, data manager, senior nurse, two PhD students, advanced trainee registrars and medical students. I am actively involved teaching medical students and was awarded “Best teacher of the year” by the University of Adelaide.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor The burden of cure: Secondary malignancy after allogeneic haematopoietic stem cell transplant Doctor of Philosophy Doctorate Full Time Miss Alia Elizabeth Cibich 2024 Co-Supervisor Investigating the association between seronegative rheumatoid arthritis, calcium pyrophosphate deposition disease and myeloid neoplasms. Doctor of Philosophy Doctorate Part Time Dr Lih En Hong 2023 Co-Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani 2023 Principal Supervisor Role of Inherited and Acquired Genetic Changes in the Molecular Pathogenesis of Therapy-Related Myeloid Neoplasms Doctor of Philosophy Doctorate Full Time Dr Deepak Singhal 2022 Co-Supervisor A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery Doctor of Philosophy Doctorate Full Time Miss Maha Kamel 2019 Co-Supervisor Frailty in Patients with Haematological Malignancies Doctor of Philosophy Doctorate Part Time Dr Angela Teresa Molga -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2018 - 2022 Co-Supervisor Evaluating the Role of Bone Marrow Microenvironment in the Pathogenesis of Therapy-related Myeloid Neoplasms Doctor of Philosophy Doctorate Full Time Mrs Monika Maria Kutyna
Connect With Me
External Profiles